Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study
Titel:
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study
Auteur:
Saad, Fred Efstathiou, Eleni Attard, Gerhardt Flaig, Thomas W Franke, Fabio Goodman Jr, Oscar B Oudard, Stéphane Steuber, Thomas Suzuki, Hiroyoshi Wu, Daphne Yeruva, Kesav De Porre, Peter Brookman-May, Sabine Li, Susan Li, Jinhui Thomas, Shibu Bevans, Katherine B Mundle, Suneel D McCarthy, Sharon A Rathkopf, Dana E